Metagenomi Inc. Common Stock

MGX | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.15

+$0.03 (+2.68%)

Sep 22, 2026, 11:24 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.68%

(1D)

Rating

Updated: Sep 18, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $43.29M

1D Range

1.07 1.15

52W Range

1.07 3.95

Valuation (TTM)

PE -0.45

PB 0.37

EV/EBITDA 0.46

Valuation (NTM)

Forward PE N/A

Forward PEG 0.02

Price Target $14.50

Cash Flow

FCF Yield -203.5%

SBC Adj. FCF Yield -228.4%

SBC Impact -12.3%

Margins

Gross Margin 74.3%

Operating Margin -741.6%

FCF Margin -632.7%

Growth (CAGR)

Revenue 3Y | 5Y -23.7% | N/A

Dil EPS 3Y | 5Y -10.7% | N/A

FCF 3Y | 5Y 10.4% | N/A

Returns

ROA -53.8%

ROE -63.6%

ROIC -65.9%

Financial Health

Net Cash

$82.94M

Current Ratio 4.50

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sou...

Sector Healthcare

Industry Biotechnology

Employees 113

IPO Date Feb 8, 2024

Website www.metagenomi.co

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 10, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$14.50

Upside

+1160.87%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞